We are proud to announce that Dr. Zanos’s groundbreaking research on ketamine has achieved exceptional recognition within the scientific community. According to a recent publication in the European Archives of Psychiatry and Clinical Neuroscience, Dr. Zanos’s work constitutes the top three most cited papers on ketamine and its enantiomers for depression from 2000 to 2023.

1. “NMDAR inhibition-independent antidepressant actions of ketamine metabolites” published in Nature (2016) has been cited more than 1500 times, highlighting its significant impact on understanding ketamine’s mechanisms beyond NMDAR inhibition.
2. “Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms” published in Pharmacological Reviews (2018) with 1000 citations, offers comprehensive insights into the pharmacological profiles and therapeutic potentials of ketamine and its metabolites.
3. “Mechanisms of ketamine action as an antidepressant” published in Molecular Psychiatry (2018), cited 890 times, delves into the underlying mechanisms by which ketamine exerts its rapid antidepressant effects.

These highly influential papers underscore Dr. Zanos’s leading role in advancing the field of ketamine research, providing critical insights into its therapeutic potential for treating depression and other brain diseases. His work continues to shape the scientific discourse and drive forward new avenues for clinical applications.